VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin.
Rossini. Lara L; Hashimoto. Yuichi Y; Suzuki. Hiroaki H; Kurita. Megumi M; Gianfriddo. Marco M; Scali. Carla C; Roncarati. Renza R; Franceschini. Davide D; Pollio. Giuseppe G; Trabalzini. Lorenza L; Terstappen. Georg C GC; Matsuoka. Masaaki M; Caricasole. Andrea A
Key Findings
- VSTM2L directly binds Humanin in yeast and mammalian cells
- VSTM2L is secreted, present in serum, and selectively expressed in the central nervous system
- VSTM2L acts as a strong antagonist, diminishing Humanin’s neuroprotective effects in bioassays
Practical Outcomes
- If you use Humanin supplements, be aware that your body may produce VSTM2L, which could limit its effectiveness. Future approaches might look at ways to lower VSTM2L levels or time Humanin dosing to avoid its antagonism, but no specific protocol changes are recommended yet.
Summary
Scientists discovered a protein called VSTM2L that sticks to the anti‑aging peptide Humanin and blocks its brain‑protective actions. This natural blocker is found in the blood and brain, meaning it could reduce the benefits of taking Humanin as a supplement.
Abstract
Humanin (HN) is a 24-residue peptide displaying a protective activity in vitro against a range of cytotoxic and neurotoxic insults, as well as mediating in vivo amelioration of Alzheimer disease (AD)-related memory impairment in experimental models. Published evidence suggests that the mechanisms through which HN exerts its cyto- and neuroprotective activity may include its secretion and binding to membrane-associated receptors. Here, we describe the identification of a new modulator of HN neuroprotective activity, V-set and transmembrane domain containing 2 like (VSTM2L), previously known as C20orf102. VSTM2L interacts with HN in both yeast and mammalian cells, is secreted in cultured cells, is present in serum, and is selectively expressed in the central nervous system. VSTM2L colocalizes with HN in distinct brain areas as well as in primary cultured neurons, where it plays a role in the modulation of neuronal viability. When tested in HN neuroprotection bioassays, VSTM2L acts as a strong antagonist of HN neuroprotective activity. In summary, VSTM2L is the first example of a secreted antagonist of HN and may play a role in the modulation of HN biological functions.
Study Information
pubmed
2011
2011-03-10T00:00:00.000Z
10.1096/fj.10-163535
30
46